We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+5.49%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$607M
AUM Growth
+$64.8M
Cap. Flow
+$73M
Cap. Flow %
12.03%
Top 10 Hldgs %
61%
Holding
61
New
22
Increased
13
Reduced
4
Closed
21

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$22M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$19.8M
3
CORT icon
Corcept Therapeutics
CORT
+$19.4M
4
PCRX icon
Pacira BioSciences
PCRX
+$17M
5
AZN icon
AstraZeneca
AZN
+$16.8M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$19.5M
2
ABLX
Ablynx NV
ABLX
+$15.9M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11M
4
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
+$9.16M
5
VTRS icon
Viatris
VTRS
+$8.92M

Sector Composition

Rank Sector Weight
1 Healthcare 62.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYNB
26
Kyntra Bio
KYNB
$27.5M
$6.97M 1.15%
6,036
-1,998
-25% -$2.63M
KURA icon
27
Kura Oncology
KURA
$826M
$6.6M 1.09%
351,955
-93,595
-21% -$1.82M
SLGL icon
28
Sol-Gel Technologies
SLGL
$278M
$5.33M 0.88%
+51,787
New +$5.8M
ABEO icon
29
Abeona Therapeutics
ABEO
$369M
$5.3M 0.87%
+14,780
New +$5.49M
PRGO icon
30
Perrigo
PRGO
$1.43B
$4.65M 0.77%
+55,748
New +$4.86M
TVRD
31
Tvardi Therapeutics
TVRD
$19.7M
$4.35M 0.72%
+9,751
New +$4.73M
MDGL icon
32
Madrigal Pharmaceuticals
MDGL
$11.4B
$4.23M 0.7%
+36,226
New +$4.47M
ONCS
33
DELISTED
OncoSec Medical Incorporated
ONCS
$3.88M 0.64%
+9,383
New +$3.85M
LUMO
34
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$3.63M 0.6%
+55,556
New +$3.94M
ZSAN
35
DELISTED
Zosano Pharma Corporation
ZSAN
$3.53M 0.58%
+20,000
New +$6.69M
LRMR icon
36
Larimar Therapeutics
LRMR
$398M
$2.99M 0.49%
33,463
+19,177
+134% +$1.63M
ADVM
37
DELISTED
Adverum Biotechnologies
ADVM
$2.91M 0.48%
+50,118
New +$3.12M
YARW
38
Yarrow Bioscience, Inc. Common Stock
YARW
$22M
$2.79M 0.46%
+21
New +$2.55M
XENE icon
39
Xenon Pharmaceuticals
XENE
$6.2B
$1.86M 0.31%
+379,071
New +$1.4M
QTTB icon
40
Q32 Bio
QTTB
$462M
$243K 0.04%
+722
New +$243K
ALNY icon
41
Alnylam Pharmaceuticals
ALNY
$27.4B
– –
-86,293
Closed -$11M
ANIP icon
42
ANI Pharmaceuticals
ANIP
$1.83B
– –
-41,905
Closed -$2.7M
ATRA icon
43
Atara Biotherapeutics
ATRA
$73.6M
– –
-11,466
Closed -$5.19M
AVDL
44
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-505,921
Closed -$4.15M
AZN icon
45
CALL
AstraZeneca
AZN
$266B
– –
-233,300
Closed -$16.2M
BMY icon
46
CALL
Bristol-Myers Squibb
BMY
$132B
– –
-295,600
Closed -$18.1M
CTMX icon
47
CytomX Therapeutics
CTMX
$714M
– –
-179,870
Closed -$3.8M
CBIO
48
Crescent Biopharma
CBIO
$555M
– –
-4,804
Closed -$8.07M
KALV
49
DELISTED
KalVista Pharmaceuticals
KALV
– –
-180,794
Closed -$1.76M
MRK icon
50
Merck
MRK
$321B
– –
-362,915
Closed -$19.5M
1
2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Nexthera Capital held 61 positions worth $607M, up 12% from $542M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Nexthera Capital deployed $73M of net new capital in Q1 2018, opening 22 new positions and adding to 13 existing holdings. Its largest new stake was Bristol-Myers Squibb: 342,399 shares worth $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 48% a quarter earlier.

On the sell side, the largest reduction was Viatris, an estimated $8.92M trimmed.

  • Nexthera Capital's largest Q1 2018 buy was Bristol-Myers Squibb: 342,399 shares worth $21.7M.
  • Nexthera Capital added most to Immunomedics Inc in Q1 2018, an estimated $11.1M increase.
  • Nexthera Capital's biggest Q1 2018 reduction was Viatris, cutting an estimated $8.92M.
  • Nexthera Capital fully exited Merck in Q1 2018, selling an estimated $19.5M.
  • Nexthera Capital's ten largest holdings make up 61% of its $607M portfolio in Q1 2018.
  • Nexthera Capital opened 22 new positions and closed 21 in Q1 2018.
  • Nexthera Capital's portfolio value rose 12% quarter-over-quarter to $607M.

Based on Nexthera Capital's 13F filing for Q1 2018, filed 15 May 2018.